Introducing the AirFit F40: Experience Unprecedented Freedom with the Comfort and Optimized Seal Performance of ResMed’s Smallest Full-Face CPAP Mask
06 Marzo 2024 - 8:05AM
ResMed (NYSE: RMD, ASX: RMD), a global leader in digital health and
cloud-connected medical devices that transform care for people with
sleep apnea and other chronic respiratory diseases, today announced
the U.S. launch of the AirFit F40, an ultra-compact, full-face mask
offering the comfort of smaller masks without sacrificing
performance in order to help improve sleep apnea therapy
compliance.2
Finding the right mask with the right fit and comfort can be
daunting, especially for individuals requiring high-pressure CPAP
treatment. The AirFit F40 addresses this problem by providing the
necessary pressure support in a more comfortable, lower-profile
full-face mask. The mask is ideal for people who sleep on their
side, are claustrophobic, and want the stability and seal of a
universal fit mask in a minimalist design. In a ResMed clinical
study, 88% of patients rated AirFit F40's mask cushion as soft and
comfortable and 100% found AirFit F40 easy to use.3
"Most users prefer smaller and more streamlined masks, but
traditional under-the-nose full-face masks can be challenging to
fit properly, maintain a seal, and handle higher pressures. Our new
AirFit F40 addresses this problem by offering the best of both
worlds: an ultra-compact full-face mask with the high seal
performance of an over-the-nose mask – bridging the gap between
compactness and effectiveness in full-face masks,” said Justin
Leong, ResMed chief product officer.
A key feature of the AirFit F40 is the AdaptiSeal™ cushion, a
100% soft silicone cushion designed to maintain a facial seal, even
when moving around during sleep. Additional features include:
- A fully flexible frame that keeps the assembly away from
patients’ eyes and ears.
- A full-face mask with a quick-release short tube, reducing tube
drag and offering a convenient way to detach and reattach the mask
to the device during the night.
- Headgear without top strap adjustment, which makes for an
easier setup and adjustment process.
- A new textile material and a dark grey color, offering a more
modern look.
AirFit F40 is the latest in ResMed’s family of innovative CPAP
masks, connected devices, and digital health technologies for
helping millions with sleep apnea, COPD, and other chronic diseases
sleep, breathe, and live better.
AirFit F40 masks are available in the U.S., with plans to launch
in Canada, followed by EMEA, Latin America, and APAC. For more
information, visit ResMed.com/AirFitF40.
About ResMedAt ResMed (NYSE: RMD, ASX: RMD) we
pioneer innovative solutions that treat and keep people out of the
hospital, empowering them to live healthier, higher-quality lives.
Our digital health technologies and cloud-connected medical devices
transform care for people with sleep apnea, COPD, and other chronic
diseases. Our comprehensive out-of-hospital software platforms
support the professionals and caregivers who help people stay
healthy in the home or care setting of their choice. By enabling
better care, we help improve quality of life, reduce the impact of
chronic disease, and lower costs for consumers and healthcare
systems in more than 140 countries. To learn more,
visit ResMed.com and follow @ResMed.
For
media +1
858.289.7272 news@resmed.com
For investors+1
858.836.5000investorrelations@resmed.com
1, 3 ResMed external clinical studies of current PAP users with
≥ 12 months’ therapy with either ResMed or competitor masks and who
met 90-day compliance in the three months prior to the study. All
participants used the ResMed AirFitF40 and a competitor mask for up
to seven nights each at randomized order. Studies conducted in the
U.S., October 4 -November 20, 2023. n=57.
2 Compliance is defined by the CMS as certain number of hours
per night, and number of nights of use within first 90 days.
ResMed (NYSE:RMD)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
ResMed (NYSE:RMD)
Gráfica de Acción Histórica
De May 2023 a May 2024